Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

DISEASE CHARACTERISTICS: Phase I (closed to accrual as of 10/15/2007) * Histologically or cytologically confirmed solid tumor or hematologic malignancy, including, but not limited to, any of the following: * Breast cancer * Ovarian cancer * Myeloid or lymphoid leukemia * Hodgkin or non-Hodgkin lymphoma * Multiple myeloma * Measurable or evaluable disease * Must meet 1 of the following criteria: * Refractory to at least one prior conventional treatment regimen * Not a candidate for conventional therapy * No conventional therapy exists * No clinically or radiographically significant pleural or pericardial effusion * Patients with ascites may be eligible at the discretion of the investigator * Previously treated central nervous system disease allowed provided it has been stable for \> 3 months and it is not the only site of measurable disease * Not eligible for a higher priority protocol Phase II * Diagnosis of breast cancer * Metastatic disease * Measurable disease by RECIST criteria * No symptomatic brain metastases * Patients with treated brain metastases that have been stable for \> 3 months and does not require chronic steroids are eligible * Hormone receptor status not specified PATIENT CHARACTERISTICS: Phase I (closed to accrual as of 10/15/2007) * Karnofsky performance status 60-100% * Life expectancy ≥ 2 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * WBC ≥ 2,000/mm³ * ANC…